A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity
<i>E. coli</i> L-asparaginase is an amidohydrolase (EC 3.5.1.1) which has been successfully used for the treatment of Acute Lymphoblastic Leukemia for over 50 years. Despite its efficacy, its side effects, and especially its intrinsic immunogenicity, hamper its usage in a significant sub...
Guardado en:
Autores principales: | Maristella Maggi, Greta Pessino, Isabella Guardamagna, Leonardo Lonati, Cristina Pulimeno, Claudia Scotti |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0aec481af2694847a11eac4671973910 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
REMISSION RATE OF PRE-B ALL (ACUTE LYMPHOBLASTIC LEUKEMIA) AFTER INDUCTION CHEMOTHERAPY FOLLOWING UNITED KINGDOM ACUTE LYMPHOBLASTIC LEUKAEMIA 2011 (UKALL 2011) TRIAL PROTOCOL
por: Hafiz Muhammad Murtaza, et al.
Publicado: (2021) -
Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential
por: Yu Y, et al.
Publicado: (2017) -
Osteonecrosis as the presenting feature in a child with acute lymphoblastic leukaemia
por: Lim Sern Chin, et al.
Publicado: (2021) -
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study
por: Dong Won Baek, et al.
Publicado: (2021) -
Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
por: Francisca Villanueva-Flores, et al.
Publicado: (2021)